These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29660005)

  • 61. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
    Schlumberger M; Elisei R; Müller S; Schöffski P; Brose M; Shah M; Licitra L; Krajewska J; Kreissl MC; Niederle B; Cohen EEW; Wirth L; Ali H; Clary DO; Yaron Y; Mangeshkar M; Ball D; Nelkin B; Sherman S
    Ann Oncol; 2017 Nov; 28(11):2813-2819. PubMed ID: 29045520
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
    Sorensen AG; Batchelor TT; Zhang WT; Chen PJ; Yeo P; Wang M; Jennings D; Wen PY; Lahdenranta J; Ancukiewicz M; di Tomaso E; Duda DG; Jain RK
    Cancer Res; 2009 Jul; 69(13):5296-300. PubMed ID: 19549889
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
    Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
    Huang S; Michalek JE; Reardon DA; Wen PY; Floyd JR; Fox PT; Clarke GD; Jerabek PA; Schmainda KM; Muzi M; Hyun H; Lee EQ; Brenner AJ
    Sci Rep; 2021 Apr; 11(1):7632. PubMed ID: 33828310
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
    Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H
    Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
    Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
    Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
    [TBL] [Abstract][Full Text] [Related]  

  • 70. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
    Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.
    LaViolette PS; Cohen AD; Prah MA; Rand SD; Connelly J; Malkin MG; Mueller WM; Schmainda KM
    Neuro Oncol; 2013 Apr; 15(4):442-50. PubMed ID: 23382287
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
    Schmainda KM; Prah MA; Zhang Z; Snyder BS; Rand SD; Jensen TR; Barboriak DP; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1132-1139. PubMed ID: 31248863
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
    Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
    J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
    Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
    Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U
    Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
    Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
    Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
    Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
    J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.